Promediol SA is a Swiss company that deals with the research, production and marketing of pharmaceutical grade products based on cannabis for the treatment of various pathologies, especially in the neurological field. For some years now the company has been exporting and selling their prescription drugs to several countries.
Promediol SA operates in full compliance with GMP and GDP rules. Their Brazilian branch, Promediol do Brasil Ltda, is approved by Anvisa and handles operations in Latin America.
Promediol full-spectrum cannabis extract was among the first prescription products authorized by Anvisa for marketing in Brazil.
A Promediol 6000 CBD formulation is currently under ANVISA evaluation and its approval is expected shortly. A number of new products are at various stages of development and will be soon submitted to the health authority for evaluation.
Promediol SA is interested in establishing alliances with strategic partners aimed at developing business in other Countries worldwide.

A brief description of Promediol products follows.